Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + etanercept
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Celecoxib + etanercept is a combination of two pharmaceutical agents used in the management of inflammatory conditions, particularly ankylosing spondylitis and potentially other rheumatic diseases. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor classified as a nonsteroidal anti-inflammatory drug (NSAID), which reduces inflammation and pain by inhibiting prostaglandin synthesis. Etanercept is a biologic agent that acts as a dimeric fusion protein mimicking the tumor necrosis factor receptor (TNFR), binding to and neutralizing tumor necrosis factor alpha (TNF-α), thereby modulating immune responses involved in chronic inflammation. The combination has been studied for its efficacy in reducing MRI-detected inflammation and improving clinical outcomes in active ankylosing spondylitis, with evidence suggesting superior efficacy compared to celecoxib alone[8][4]. Both drugs are approved individually for use in rheumatoid arthritis, ankylosing spondylitis, and related conditions[3][5].
- Brand names
- Enbrel + Celebrex
- Other names
- etanercept plus celecoxibEnbrel plus CelebrexEtanercept and Celecoxib Combined Treatment
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on celecoxib + etanercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + etanercept.